14.9 C
New York
Tuesday, September 26, 2023

An Evaluation Of Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Eagle Pharmaceuticals Inc. (EGRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $17.81. The Eagle Pharmaceuticals Inc. has recorded 1,145 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

EGRX belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $17.81 and fluctuated between $18.16 as its day high and $17.16 as its day low. The current market capitalization of Eagle Pharmaceuticals Inc. is $220.13M. A total of 0.15 million shares were traded on the day, compared to an average of 205.62K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, EGRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 15 SELLs from insiders. Insiders purchased 89,400 shares during that period but sold 80,771.

In the most recent transaction, Tarriff Scott sold 15,000 shares of EGRX for 19.98 per share on May 16. After the transaction, the CEO now owns 587,311 company shares. In a previous transaction on May 15, Tarriff Scott sold 15,000 shares at 21.07 per share. EGRX shares that CEO owns now total 1,594,934.

Among the insiders who sold shares, Tarriff Scott disposed of 15,000 shares on May 12 at a per-share price of $20.27. This resulted in the CEO holding 1,609,934 shares of EGRX after the transaction. In another insider transaction, Tarriff Scott sold 15,000 shares at $20.71 per share on May 11. Company shares held by the CEO now total 1,624,934.



While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for EGRX in the last 3 months, the mean price target is $17.00 with high estimates of $17.00 and low estimates of $17.00. In terms of 52-week highs and lows, EGRX has a high of $40.85 and a low of $16.19.

As of this writing, EGRX has an earnings estimate of $0.98 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of $1.06 per share and a lower estimate of $0.91. The company reported an EPS of $1.26 in the last quarter, which was 20.00% higher than expectations of $1.05.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. EGRX’s latest balance sheet shows that the firm has $97.66M in Cash & Short Term Investments as of fiscal 2021. There were $25.61M in debt and $74.38M in liabilities at the time. Its Book Value Per Share was $19.25, while its Total Shareholder’s Equity was $176.45M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EGRX is Buy with a score of 3.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles